News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The agreement will facilitate the establishment of the IITK-UB Joint Center of Excellence in Biomedicine and Bioengineering
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The approval comes soon after Corbevax was given the nod for 12-15-year group
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Govt announces vaccination programme for kids and those above 60 years of age
The award recognizes and supports promising women scientists
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Subscribe To Our Newsletter & Stay Updated
